The risk for treatment failure and hospital readmission was lower among patients with MSSI BSIs who received high- vs standard-dose daptomycin as OPAT after discharge.

Avacincaptad pegol and pegcetacoplan have similar 12-month outcomes in slowing GA, with pegcetacoplan requiring fewer injections.